Search Results

Replay, a genome writing company reprogramming biology by writing and delivering big DNA, announced the launch of Eudora, an HSV gene therapy company targeting genetic retinal diseases.

Kedalion Therapeutics, Inc., a clinical-stage company focused on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream™ platform, today announced a shift in its management team as current CEO, Peter Noymer, Ph.D., transitions from the company to pursue new opportunities.

Oyster Point Pharma announced the close of a Series A financing worth $22M.

A Biotechnology Industry Leader and Internationally Known Vitreo-Retinal Specialist with Notable Expertise in Pharmaceuticals for Age-Related Macular Degeneration and Ocular Gene Therapy – NEW YORK--( BUSINESS WIRE )-- IVERIC bio, Inc. (NASDAQ: ISEE) announced today the election of Mark S. Blumenkranz, M.D., M.M.S., HJ Smead Professor Emeritus of Ophthalmology at Stanford University, to its Board of Directors, effective as of July 15, 2020. D